MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.1 USD | +1.79% |
|
-1.28% | +24.67% |
| 07:45pm | Deutsche Bank Raises Moderna's Price Target to $85 From $70 | MT |
| May. 07 | UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating | MT |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 26 M€ | +16.85% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.02% | 0 M€ | +0.45% | - | |
| 0.02% | 0 M€ | +2.89% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 0 M€ | +0.44% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.01% | 0 M€ | -1.07% | - | |
| 0.01% | 0 M€ | +3.39% | - | |
| 3.94% | 0 M€ | +5.78% | - | |
| 7.45% | 0 M€ | +4.29% | - |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
121.9
USD
Average target price
138.7
USD
Spread / Average Target
+13.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.67% | 46.71B | |
| +48.83% | 41.8B | |
| -1.05% | 41.52B | |
| -5.86% | 29.55B | |
| +10.86% | 25.78B | |
| -20.48% | 19.26B | |
| +2.40% | 12.14B | |
| -2.54% | 12.08B | |
| +28.38% | 11.98B | |
| +20.97% | 11.58B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.